systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of covid-19. This article is protected by copyright. All rights reserved.Some systemic and biologic psoriasis treatments [SBT] have been associated with an increased risk of infection.1 To date, more and more data regarding the risk of COVID-19 infection in patients receiving SBT becomes available.2-5 To enrich these data, we evaluated the frequency of severe COVID-19 infections, defined as hospitalisation or death, in psoriasis patients receiving SBT, especially during the 4 months following SBT initiation.